Nanoscale Therapy Delivered Via Nose-to-Brain Route Shows Promise in Glioblastoma Treatment
Glioblastoma, one of the moast aggressive and challenging brain cancers to treat, has long resisted conventional therapies. Now,a groundbreaking study from researchers at Washington University School of Medicine and Northwestern University offers a beacon of hope: a novel nanoscale therapy delivered directly to the brain via the nasal passages,demonstrating meaningful tumor reduction and long-lasting immunity in preclinical models. This innovative approach, detailed in recent research, represents a critical step towards more effective and less toxic treatments for glioblastoma and perhaps other immune-resistant cancers.
The Challenge of Brain Cancer Treatment & The Promise of Nose-to-Brain Delivery
The blood-brain barrier (BBB), a protective mechanism designed to shield the brain from harmful substances, also presents a major obstacle for delivering cancer therapies. Customary systemic treatments often struggle to reach therapeutic concentrations within the brain, limiting their effectiveness. Directly injecting drugs into the brain is invasive and carries its own risks.
Recognizing this limitation, researchers have been exploring alternative delivery routes, with intranasal delivery gaining traction. The nasal passages offer a unique pathway, bypassing the BBB via the olfactory and trigeminal nerves, providing a more direct route to the brain.Though, achieving targeted delivery and robust immune activation with nanoscale therapies via this route has remained elusive – until now.
Harnessing the Power of Spherical Nucleic Acids (SNAs)
The breakthrough hinges on the progress of specialized spherical nucleic acids (SNAs), nanoscale particles pioneered by Dr. Chad A. Mirkin of Northwestern University. SNAs are densely coated with DNA or RNA,offering superior delivery capabilities compared to traditional methods. This research team engineered SNAs with gold nanoparticle cores and short DNA fragments specifically designed to activate the STING (Stimulator of Interferon Genes) pathway.
“We’ve been working to overcome the challenges of delivering effective immunotherapy to glioblastoma for years,” explains Dr. Alexander Stegh,led author of the study. “The key was finding a way to not only reach the tumor, but also to stimulate the immune system within the tumor microenvironment.”
Targeted Immune Activation & Precise Delivery
The SNAs were administered as “nanodrops” via the nasal passages of mice with glioblastoma. Researchers utilized a molecular tag that fluoresces under near-infrared light to meticulously track the particles’ journey. Imaging revealed the SNAs traveling along the nerve pathways connecting the nasal cavity to the brain, demonstrating targeted delivery.
Crucially,the therapy triggered a concentrated immune response within the tumor itself,activating STING in key immune cells. This activation was further confirmed by observing activity in nearby lymph nodes, indicating a localized immune response with minimal systemic spread – a significant advantage in minimizing potential side effects.
Synergistic Effects & Long-Lasting Immunity
The real power of this approach emerged when the SNA nanotherapy was combined with treatments designed to activate T lymphocytes, another critical component of the immune system. This synergistic combination resulted in complete tumor elimination in the treated mice and,remarkably,induced long-lasting immunity that prevented cancer recurrence. These outcomes surpassed those observed with existing STING-targeting therapies.
“stimulating the STING pathway alone isn’t enough to overcome the complex immune suppression mechanisms employed by glioblastoma,” Dr. Stegh emphasizes. “Our ongoing research focuses on incorporating additional immune-activating features into these nanostructures to address multiple therapeutic targets concurrently.”
Looking Ahead: towards Clinical Translation
This research represents a significant advancement in the field of brain cancer treatment. The successful presentation of targeted delivery, localized immune activation, and long-lasting anti-tumor immunity provides a strong foundation for future clinical trials.
“This is an approach that offers real hope for safer,more effective treatments for glioblastoma and potentially other cancers that have proven resistant to immunotherapy,” Dr. Stegh concludes. “It’s a critical step towards translating this research into tangible benefits for patients.”
Study Funding & Transparency
This research was generously supported by grants from the National Cancer Institute of the NIH (P50CA221747, R01CA275430, R01CA120813, R01NS120547, R01CA272639), the Melanoma Research Foundation, the Chicago Cancer Baseball Charities, and grants from Cellularity, Alnylam, and AbbVie. Imaging support was provided by NIH instrumentation grants and the Robert H. Lurie Comprehensive cancer Center.
*Notably Dr. Stegh holds a financial interest in Exicure Inc., a company developing SNA therapeutic platforms, and Dr. Mirkin is a shareholder in Flashpoint, which develops SNA
Worth a look